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Abstract
Background: Tandem mass spectrometry (MS/MS) has been available in China for 8 years. This technique makes it
possible to screen for a wide range of previously unscreened inborn errors of metabolism (IEM) using a single test.
This 3-year pilot study investigated the screening, diagnosis, treatment and outcomes of IEM in symptomatic
infants and children.
Methods: All children encountered in the Newborn Screening Center of Zhejiang Province during a 3-year period
with symptoms suspicious for IEM were screened for metabolic diseases. Dried blood spots were collected and
analyzed by tandem mass spectrometry. The diagnoses were further confirmed by clinical symptoms and
biochemical analysis. Neonatal intrahepatic cholestasis caused by citrin deficiency, ornithine transcarbamylase
deficiency and primary carnitine deficiency were confirmed by DNA analysis.
Results: A total of 11,060 symptomatic patients (6,720 boys, 4,340 girls) with a median age of 28.8 months (range:
0.04-168.2 months) were screened. Among these, 62 were diagnosed with IEM, with a detection rate of 0.56%.
Thirty-five were males and 27 females and the median age was 3.55 months (range 0.07-143.9 months). Of the 62
patients, 27 (43.5%) had aminoacidemias, 26 (41.9%) had organic acidemias and nine (14.5%) had fatty acid
oxidation disorders.
Conclusions: Because most symptomatic patients are diagnosed at an older age, mental retardation and motor delay
are difficult to reverse. Additionally, poor medication compliance reduces the efficacy of treatment. More extensive
newborn screening is thus imperative for ensuring early diagnosis and enhancing the treatment efficacy of IEM.
Keywords: Tandem mass spectrometry, Inborn errors of metabolism, Aminoacidemia, Fatty acid oxidation disor-
ders, Organic acidemia
Background
The use of tandem mass spectrometry (MS/MS) in new-
born screening makes it possible to screen for a wide
range of previously unscreened inborn errors of metabo-
lism (IEM) using a single test [1] The disease profile
includes aminoacidemias, fatty acid oxidation (FAO) dis-
orders and organic acidemias. Early screening and diag-
nosis may help to decrease mortality and morbidity
rates in children with IEM.
MS/MS has been available in China for 8 years, since
its first use for IEM detection in Shanghai in 2003.
However, only five cities or provinces (Beijing, Shanghai,
Wuhan, Guangdong Province and Zhejiang Province) in
China currently screen for IEM using MS/MS in symp-
tomatic infants or newborns. The Newborn Screening
Center of Zhejiang Province is the largest screening cen-
ter in China, and initially implemented MS/MS for
screening 26 treatable metabolic disorders in sympto-
matic infants in 2008, and expanded this to newborn
screening in 2009. However, MS/MS newborn screening
is not currently mandatory, and only 10% of annual
births in Zhejiang Province are screened [2] Samples
from symptomatic patients with suspected IEM from
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sent to the Newborn Screening Center of Zhejiang Pro-
vince. The cost of MS/MS screening in symptomatic
infants is 390 RMB (around $59.72). None of the fees
for screening, diagnosis or treatment are covered by
medical insurance.
In this 3-year pilot study, we investigated the screen-
ing, diagnosis, treatment and outcomes of IEM in symp-
tomatic infants and children.
Methods
Study subjects
All symptomatic children at the Newborn Screening Cen-
ter of Zhejiang Province during a 3-year period were
screened for metabolic diseases. Symptomatic children
included those with symptoms suspicious for IEM includ-
ing metabolic acidosis, jaundice, hepatosplenomegaly,
recurrent vomiting, hypoglycemia, hyperammonemia,
mental retardation of unknown cause, language retarda-
tion, seizures and unconsciousness. Patients with perinatal
brain injury, central nervous system infections, brain
trauma, toxicology, tumors and chromosome anomalies
were excluded from the study. This study was approved by
the Ethical Committee of Children’s Hospital, Zhejiang
University School of Medicine. Parent consents were
obtained for publication of the children’s clinical details.
Mass spectrometry materials and equipment
Dried blood spots were collected from all patients on
Whatman 903 filter paper (Wallac OY Turku, Finland).
Blood spots were analyzed using electrospray ionization
liquid chromatography-mass spectrometry (LC-MS) with
a Quattro Micro API (Waters, MA, USA) tandem mass
spectrometer. All procedures for sample preparation and
MS analysis were performed NeoGram AAAC Spectro-
metry kit (Perkin Elmer, MA, USA) according to the
manufacturer’s protocol. Briefly, single disks were
punched from each dried blood spot using an automatic
or manual 3-mm punch. One disk was added per well.
It was recommended to use the first 2-14 wells as
blanks for every plate, to allow the LC system and mass
spectrometer to synchronize. Using a multichannel pip-
ette and reverse pipetting, 90 μlo ft h ed a i l yw o r k i n g
extraction solution (containing a mixture of the respec-
tive stable-isotope-labeled internal standards) was added
to each well. The plate was shaken and incubated, and
60 μl of the solution was then transferred to a V-bot-
tomed, heat-resistant microplate and evaporated to dry-
ness on a heating block at 55°C under nitrogen. A
volume of 50 μlo f3 . 0Nb u t a n o l i cH C lw a sp i p e t t e d
into each sample and incubated for 30 minutes at 60°C.
After incubation, the solution was again evaporated to
dryness on a heating block at 55°C under nitrogen. Deri-
vatized samples were then reconstituted with 75 μlo f
NeoGram AAAC reconstitution solution and the plate
was covered with aluminum foil, followed by incubation
at 27°C for 10 minutes. The plate was finally placed in
the autosampler for testing.
Eight amino acids, including citrulline (Cit), phenylala-
nine (Phe), methionine (Met), tyrosine (Tyr), valine
(Val), leucine (Leu), arginine (Arg), ornithine (Orn), and
20 acylcarnitines were analyzed. The acylcarnitines ana-
lyzed included C0, C2, C3, C3DC, C4, C5, C5:1, C5DC,
C5OH, C6, C8, C10, C12, C14, C16, C18, C18:1,
C16OH, C18OH, and C18:1OH. The indexes and
related disorders are shown in Table 1.
Cut-off values
The borderline cut-off values were determined by a pilot
study of acylcarnitines and amino acids in 12,720 full-
term newborns. The cut-off value was set at four stan-
dard deviations (SDs) above or lower the mean value
(Table 1). All cut-offs were modified in light of the
results of further analyses and more clinical data.
Patients were referred immediately for confirmatory
tests if the results were above the cut-off value. Repeat
analysis of the same sample was performed when the
results were outside the cut-off value. Patients were
referred for confirmatory tests if the second analysis was
also outside the cut-off value.
Confirmatory tests
Confirmatory tests included repeat MS/MS analysis,
urinary organic acid analysis by GC-MS, amino acid
analysis, routine blood analysis, biochemistry, blood gas
analysis, blood glucose and ammonia tests, blood homo-
cysteine, lactate and pyruvate tests, urine acetone tests,
biotin, biotin enzyme profile and DNA analysis. Urop-
terin profile analysis and aminoacidemias were con-
firmed by blood amino acid profile analysis and urine
GC/MS analysis; neonatal intrahepatic cholestasis
caused by citrin deficiency (NICCD), ornithine transcar-
bamylase (OTC) deficiency and primary carnitine defi-
ciency (PCD) were confirmed by DNA analysis; blood
dihydropteridine reductase activity test and BH4 loading
test were performed to subclassify hyperphenylalanine-
mia (HPA) into phenylketonuria (PKU) and BH4 defi-
ciencies. The diagnosis of organic acidemias depended
mainly on urine GC/MS analysis, and multiple carboxy-
lase deficiency (MCD) was confirmed by biotin and bio-
tin enzyme profile analysis. PCD was confirmed by
g e n e t i ca n a l y s i s .A l lt h et e s t sw e r ed o n ei no u rl a b o r a -
tory, except for the genetic analyses that were performed
in the Genetic Metabolic Laboratory of the Women and
Children’s Hospital of Beijing University, Shanghai
Genetic and Metabolic Institute, and the Genetic Meta-
bolic Laboratory of Tongji Medical School, Huazhong
University of Science and Technology.
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A total of 11,060 symptomatic patients (6,720 boys,
4 , 3 4 0g i r l s )w i t ham e d i a na g eo f2 8 . 8m o n t h s( r a n g e :
0.04-168.2 months) were screened. Among the screened
patients, 62 were diagnosed with IEM, with a detection
rate of 0.56%. Thirty-five were males and 27 females,
and the median age was 3.55 months (range: 0.07-143.9
months). Of the patients, 27 (43.5%) had aminoacide-
mias, 26 (41.9%) had organic acidemias and nine (14.5%)
had FAO disorders. Parental consanguinity was found in
one patient with 3-hydroxy-3-methylglutaryl (HMG)
CoA lyase deficiency, and a family history of IEM was
reported in three patients.
Aminoacidemias
The most common aminoacidemia was PKU (11
patients, 40.7%), followed by maple syrup urine disease
(MSUD) (5 patients, 18.5%), NICCD (5 patients, 18.5%),
homocystinuria, and OTC deficiency (Table 2). Seven of
the 11 PKU patients presented with language and motor
development delays, and three had convulsions and epi-
lepsy when referred for diagnosis. One of the 11 PKU
patients showed normal growth and development, but
the others still had growth retardation after treatment.
All patients with MSUD showed poor appetite, convul-
sions, septicemia, irritability, and lethargy shortly after
birth. Parents of two patients with MSUD refused treat-
ment for their children after diagnosis. All five patients
with NICCD had infant hepatitis syndrome at diagnosis,
presenting with jaundice and abnormal hepatic function
Table 1 MS/MS screening profiles
MS/MS
analytes
Cut-off value
(μmol/l)
Possible disorder(s)
Amino
acids
↑PHE > 103.18 Phenylketonuria
↑PHE/TYR > 1.43 BH4 deficiency
↑MET > 64.11 Homocystinuria
↑MET/PHE > 0.92
↑LEU > 327.51 Maple syrup urine disease
↑LEU/PHE > 4.85
↑VAL > 433.56
↑TYR > 305.87 Tyrosinemia
↑TYR/PHE > 4.00
↑CIT > 37.35 Citrullinemia
↑CIT/PHE > 0.70 Neonatal intrahepatic cholestasis caused
by citrin deficiency
↑ARG > 40.77 Argininemia
↑ARG/ORN > 0.70
↓CIT < 6.05 Ornithine transcarbamylase deficiency
↑ORN > 393.08
Organic
Acids
↑C3 > 4.33 Methylmalonic acidemia
↑C3/C2 > 0.20 Propionic acidemia
± C4DC > 1.92
↑C3DC > 0.14 Malonic acidemia
↑C3DC/C4 > 0.80
↑C4 > 0.92 Glutaric acidemia type II (multiple acyl-
CoA dehydrogenase
↑C5 > 0.69 deficiency)
↑C8 > 0.33
↑C14 > 0.59
↑C16 > 6.13
↑C12 > 0.47
↑C5 > 0.69 Isovaleric acidemia
↑C5/C2 > 0.03
↑C5DC > 0.14 Glutaric acidemia type I
↑C5DC/C8 > 2.50
↑C5OH > 0.73 3-methylcrotonyl-CoA carboxylase
deficiency
↑C 5OH/C3 > 0.13 3-OH-3-methylglutaryl-CoA lyase
deficiency
(± C5:1) > 0.12 Multiple carboxylase deficiency
(± C6DC) > 0.14
(± C3) > 4.33
↑C5:1(±
C5OH)
> 0.12 b-Ketothiolase deficiency
Fatty acid oxidation defects
↓ C0 < 15.0 Primary carnitine deficiency
↓C2 < 9.82
↑C0 > 90.0 Carnitine palmitoyltransferase I deficiency
↑C0/(C16 + > 30.00
C18)
↓C16 < 0.75
Table 1 MS/MS screening profiles (Continued)
↑C4 > 0.92 Short-chain acyl-CoA dehydrogenase
deficiency
↑C4/C2 > 0.40
↑C8 > 0.33 Medium-chain acyl-CoA dehydrogenase
deficiency
↑C8/C10 > 0.37
(± C6 (> 0.33
C10:1) > 0.29)
↑C14:1 > 0.39 Very long-chain acyl-CoA dehydrogenase
deficiency
↑C14:1/C16 > 0.29
(± C14
C16, C18:1)
↑C16 > 6.13 Carnitine palmitoyltransferase II
deficiency
↑C18 > 2.68 Carnitine-acylcarnitine translocase
deficiency
↑C18:1 > 2.7
↑C16OH > 0.21 Long-chain hydroxyacyl-CoA
dehydrogenase deficiency
↑C18OH > 0.17 Trifunctional protein deficiency
↑C18:1OH > 0.15
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function tests after treatment. Two patients with homo-
cystinuria presented with jaundice at diagnosis; one of
them developed normally with normal laboratory results
after treatment, but the other was lost to follow-up.
Two of the three patients with OTC deficiencies discon-
tinued treatment after diagnosis, and the other one
developed well after 6-months treatment with a protein-
restricted diet, and arginine and citrulline
supplementation.
FAO disorders
Nine patients had FAO disorders, of which PCD was the
most common (8/9, 89%) (Table 3). Convulsions were
the most obvious symptom in these patients, and one
presented with cardiomyopathy. Cardiac and neurologi-
cal symptoms disappeared rapidly in these patients after
supplementation with L-carnitine, with no occurrence of
metabolic disorders or sudden death. The one patient
detected with medium-chain acyl-CoA dehydrogenase
(MCAD) deficiency was a girl, aged 26 months at diag-
nosis. Her initial presentation was febrile convulsions,
and her blood C6, C8, C10 levels were elevated at
screening. She developed normally with normal bio-
chemical analysis after treatment with oral carnitine and
standard diet recommendation.
Organic acidemias
Methylmalonic acidemia (MMA) was the most common
organic acidemia in this cohort of patients, followed by
propionic acidemia (PA), MCD and glutaric acidemia type
1 (GA-I) (Table 4). Other types of organic acidemia were
rare in these patients. All patients with MMA and PA pre-
sented with hypoglycemia, metabolic acidosis, convulsions
and developmental delay. Two MMA patients died, and
the parents of the other two discontinued treatment. Two
of the four PA patients died, one from metabolic acidosis
and the other from respiratory failure. The symptoms in
the patients with GA-I varied; two presented with recur-
rent convulsions and motor developmental delay at 1 year
of age, while the other had macrocephaly and hypotonia at
4 months of age. Cranial magnetic resonance imaging
showed extensive abnormal signals in the white matter
and basal ganglia, ventriculomegaly and frontotemporal
atrophy, widened sylvian fissures (bat-wing appearance).
All three patients improved remarkably after 11, 13 and 16
months of follow-up, respectively. The patient with HMG-
CoA lyase deficiency died soon after diagnosis.
Discussion
The introduction of MS/MS into neonatal screening has
enabled the screening of conditions that might other-
wise have been missed, and thus believed to be
Table 2 Abnormal MS/MS results of aminoacidemias
Aminoacidemias (n = 27) n (%) Age at
diagnosis
Abnormal
parameter
Concentration mean (range)
(μmol/l)
Reference range
(μmol/l)
Phenylketonuria 11
(40.7%)
1.4-135.6 mon Phe 798.80 (216-1229) 28.08-103.18
Phe/Tyr 9.01 (2.02-19.87) 0.15-3.0
Maple syrup urine disease 5
(18.5%)
2-26 d Leu 3,390.57 (2,832.99-4,098.79) 88.26-327.51
Val 600.51 (358-883) 89.5-433.56
Neonatal intrahepatic cholestasis caused by
citrin deficiency
5
(18.5%)
2-4 mon Cit 219.7 (89-318) 6.05-37.35
Homocystinuria 3
(11.11%)
0.6-36 mon Met 335.5 (100-626) 10.82-64.11
Ornithine transcarbamylase deficiency 3
(11.11%)
0.07-7 mon Cit 5.28 (5.15-5.45) 6.05-37.35
Orn 398.33 (312-452) 47.53-393.08
Table 3 Abnormal MS/MS results of fatty acid oxidation disorders
Fatty acid oxidation
disorders (n = 9)
n (%) Age at
diagnosis
Abnormal
parameter
Concentration mean
(range) (μmol/l)
Reference range
(μmol/l)
Primary carnitine deficiency 8
(89%)
0.6-89
mon
C0 9.7 (0.87-14.10) 15.0-95.03
C2 5.5 (2.3-6.6) 9.82-39.9
C6 0.49 0.0-0.37
Medium-chain acyl-CoA dehydrogenase 1
(11%)
2 mon C8 0.54 0.0-0.33
C10:1 0.55 0.0-0.33
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improved the efficacy of neonatal screening programs,
demonstrating the importance of early identification and
treatment of infants with disorders that would otherwise
go unrecognized, before irreversible clinical damage
occurs [5,6].
A total of 62 of 11,060 symptomatic patients (0.56%)
were diagnosed with IEM in our study, which was
higher than the percentage in a Korean study [7], which
diagnosed 20 out of 6,795 symptomatic children with
IEM (0.29%). However, several other studies [8,9]
including one Indian and two Chinese studies, reported
even higher detection rates of 3.2%, 6.6% and 9.6%,
respectively. The wide variation in detection rates is not
surprising, given the different screening criteria for IEM
used in different countries, and the inconsistent sample-
collection methods. Samples in the study by Gu et al.
[9]. Included patients highly suspected of metabolic dis-
eases from throughout the country, while most of our
samples were from outpatients and inpatients in a single
hospital. The detection rate in our series was thus much
lower.
Amino acid disorders in our study accounted for
43.5% of total cases, with PKU being the most common
type. This proportion was similar to two previous stu-
dies [6,7]. All the HPA patients were of classical type,
and no case of BH4 deficiency was found. The age at
diagnosis of the PKU patients was much older than in
other reports [8], with a median age of 32 months
(range: 1.3-135 months). Most patients had mental and
language developmental delays at diagnosis. Apart from
one patient diagnosed at 1 month of age who showed
normal mental development after treatment, the remain-
ing 10 patients suffered from mental retardation during
follow-up, possibly as a result of older age at diagnosis.
All the PKU patients were from the neighboring
provinces including Anhui and Jiangxi Provinces.
Although newborn screening for PKU and congenital
hypothyroidism have been implemented for 30 years
with a coverage rate of 97.5% in Zhejiang Province, the
average coverage rate for newborn screening was still
below 50% over the whole country in 2010. PKU
patients may therefore not be detected at an early age in
the regions with lower coverage rates, which could
explain why all the PKU patients were from Anhui and
Jiangxi Provinces, which have low newborn screening
coverage rates. Mental retardation is difficult to reverse
in children detected by symptomatic screening at an
older age, indicating the need to improve the newborn
screening coverage rate throughout China.
The second most common disease in this study was
MSUD, as in other reports in Asian populations [4,8].
Although diagnosed at an early age (< 1 month), MSUD
patients commonly become symptomatic 4-5 days after
birth and neuropathological symptoms occur very
shortly after. Death may occur in patients without stan-
dard treatment. The patients in our study presented
with neurological symptoms such as poor feeding, dys-
tonia, poor response and somnolence, and cranial mag-
netic resonance imaging revealed abnormal signals in
the thalamus, brainstem and cerebellum at diagnosis.
Three patients showed mental and motor development
delays after treatment with a low-protein diet and spe-
cial amino acid formula. Treatment was discontinued by
the parents in two patients because of financial pro-
blems or worry about the poor outcome. MSUD had
the poorest outcome compared with other aminoacide-
mias, while NICCD had the best; all NICCD patients
recovered, with normal liver function, after treatment
with lactose-free milk powder and other medications.
Similar to other reports [6,10], FAO disorders were
uncommon in the Asian population. PCD was the most
common type of FAO disorder in the current study.
Most PCD patients were identified between 1 month
and 7 years of age, and all but one of the PCD patients
initially presented with convulsions. PCD may have a
Table 4 Abnormal MS/MS results of organic acidemias
Organic acidemias (26) n (%) Age at
diagnosis
Abnormal
parameters
Concentration mean (range)
(μmol/l)
Reference range
(μmol/l)
Methylmalonic academia 12
(46.2%)
0.1-99 mon C3 10.3 (5.1-28.77) 0.47-4.33
C3/C2 0.79 (0.11-1.88) 0.03-0.10
Propionic acidemia 4 (15.4%) 0.27-28 mon C3 12.41 (8.27-13.8) 0.47-4.33
C3/C2 1.31 (0.57-2.47) 0.03-0.10
C5OH 3.88 (2.12-5.64)
Multiple carboxylase
deficiency
4 (15.4%) 5-60 mon C3/C2 0.3 (0.290.31) 0.0-
-0.73
C3 6.58 (4.32-6.84)
Glutaric acidemia type I 3 (11.5%) 17-48 mon C5DC 1.84 (0.78-3.58) 0.03-0.14
Isovaleric acidemia 2 (7.7%) 0.27-48 mon C5 6.78 (4.21-9.35) 0.0-0.69
HMG-CoA lyase deficiency 1 (3.8%) 8 mon C5OH 10.48 0.0-0.73
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treatment. MCAD has been reported to be the most
common type of FAO in Europe and USA, and its inci-
dence was even higher than that of the aminoacidemias.
However, only one case of MCAD was found during the
present 3-year screening study, similar to the report by
Han et al., from Shanghai [11]. Other types of FAO dis-
orders are also rarely found in the Chinese population.
However, blood sampling was not performed under
strictly fasting conditions for most children, and patients
with some types of FAO may have been missed, thus
underestimating the incidence of FAO.
Organic acidemias accounted for 41.9% of IEM cases
in this study, with MMA, PA and MCD being the three
most common types. PA and MMA should be differen-
tiated by GC-MS because of their similar biochemical
results, while elevated C3 and C3/C2 ratios are much
higher in PA patients than in MMA patients. MCD had
the best outcome, and all four MCD patients recovered
dramatically after treatment with oral biotin, with no
mental developmental delay. Mental retardation per-
sisted, however, in the patients with PA and MMA
despite treatment. All GA-I patients had motor develop-
mental delay. The baby with HMG CoA lyase deficiency
deteriorated rapidly and died before diagnosis. Our
study indicated that irreversible neurological sequelae
were likely to occur if patients with organic acidemias
were not diagnosed and treated at an early stage of the
disease. Newborn screening for IEM is thus imperative.
The major limitation of this study was the cut-off
values used for screening symptomatic children. Because
these cut-off values were based on newborns, some
cases in the study population, with an age range from
0.04-168.2 months, may have been missed. Age-specific
cut-off values need to be established in further studies.
According to the report by McHugh et al. [12]. Further
validation of the cut-offs will ensure a more accurate
and early diagnosis of IEM.
The small number of diagnosed IEM patients in China
means that the experience of their treatment is still very
limited, and no uniform treatment guidelines have been
established. Poor medical compliance occurs in most
patients; treatment was discontinued by their parents in
nine children as a result of economic problems and loss
to follow-up. Of the remaining 53 patients, most still
had various symptoms, including convulsions, motor
and mental developmental delays, and language delays.
Only 10 patients become asymptomatic with normal
physical and mental development during the follow-up
period, and these 10 had all been diagnosed at a much
earlier stage and received timely treatment. This pro-
vides evidence for the importance of expanded newborn
screening throughout the province. Local governments
should consider including expanded newborn screening
in free healthcare coverage.
Conclusions
The patients in this study were all symptomatic at
screening, and most of them were beyond the neonatal
period. Because mental retardation and motor delay are
difficult to reverse in older patients with IEM, it is
essential to increase the availability of newborn screen-
ing. Additionally, IEM patients require life-long treat-
ment, and the associated costs might thus represent a
heavy burden for families with low or even middle social
economic incomes. Lack of compliance with recom-
mended treatments and medication dosages may lead to
poorer outcomes. The government should consider
increasing insurance coverage for patients with IEM in
order to improve patient compliance and consequent
treatment efficacy.
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